BPC-157

BPC-157 is a research peptide studied primarily for tissue repair and recovery. Research interest includes muscles, tendons, ligaments, joints, connective tissue, and the gastrointestinal lining. It is being studied because it may influence several biological processes involved in healing, including collagen activity, formation of new blood vessels, inflammatory signaling, and tissue regeneration.

• Tissue repair after injury
• Tendon and ligament recovery
• Muscle recovery
• Joint and connective-tissue support
• Gastrointestinal lining and gut integrity
• Inflammation-related healing

• Studied for support of collagen-related repair
• May influence new blood-vessel formation
• May affect inflammatory signaling
• May support cell and tissue regeneration
• Also studied for gastrointestinal lining support

Reconstitution

1 mL bacteriostatic water

Final concentration

10 mg/mL

Source dose

1 mg

Syringe reference

10 units = 1 mg on a U-100 syringe

Frequency

Once daily

Research duration

20 days

Administration

Subcutaneous, local to the research area, as noted on the sheet

Research duration on the sheet: 20 days, and the sheet notes the cycle may be repeated according to the research protocol.

• 10 mg + 1 mL bacteriostatic water = 10 mg/mL.
• 10 units = 1 mg.

• No dose escalation is provided on the source protocol.
• The source uses 1 mg once daily through the research cycle.

• For educational and research purposes only.
• Limited human-research data.
• Avoid use in active or recent cancer research subjects.
• Not recommended during pregnancy or breastfeeding.
• Store appropriately after reconstitution.

Human research

Limited

Animal research

Extensive

Mechanistic evidence

Strong

Long-term safety data

Limited

Completed published studies are listed below and labeled as in vitro, animal, or human research. Favorable and unfavorable results are both included, including cancer studies. This is not every paper on the compound, and it is not a recommendation or a dose.

Repair reports are animal studies. A completed human repair trial was not identified. The melanoma note is a conference abstract. In mice that already had colon tumors, BPC-157 improved wasting measures and did not produce a statistically significant drop in tumor volume.

• BPC 157 accelerates healing of a transected rat Achilles tendonAnimal

  Rats with a cut Achilles tendon recovered more function, strength, and collagen organization than saline controls.

• BPC 157 promoted tendon-to-bone healing after Achilles detachment in ratsAnimal

  Rats. The tendon-to-bone attachment healed more completely, including when a corticosteroid was also given.

• BPC 157 as therapy for a transected quadriceps muscle in the ratAnimal

  Rats. A fully cut quadriceps regained more strength, walking function, and muscle continuity over 72 days.

• BPC 157 increases new-vessel growth through VEGFR2In vitro

  Human endothelial cells formed more vessel-like tubes, and rats grew more vessels in an ischemic limb. The study did not implant a tumor. New-vessel growth is the result cancer researchers watch.

• BPC 157 and growth of a human melanoma cell lineIn vitro

  This is a conference abstract, not a full paper. In cultured human melanoma cells, BPC-157 was reported to leave fewer cells in the dividing phase. A follow-up tumor study was not identified.

• BPC 157 in mice with colon-cancer cachexiaAnimal

  Mice with C26 colon tumors. The report describes better body weight, less muscle wasting, and lower IL-6 and TNF-alpha. Tumor volume was lower on average, and that difference was not statistically significant.

10 mg vial. Format: Lyophilized powder.